Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 19, 2024
Daily News
February 19, 2024
- Active Pharma Hid Botched API Production, Source Reveals Details of Violations
February 19, 2024
- JPMA to Ponder Pricing System for New Modalities towards 2026 Reform: Chief
February 19, 2024
- Shipments Curbed or Suspended for 25.9% of Drugs in January: FPMAJ
February 19, 2024
- MHLW Announces Revised Rule for Info Disclosure of Physician Payments
February 19, 2024
- Sawai Group President Says US Biz Exit was Due to Lack of Foresight
February 19, 2024
- Vital KSK, 3 Other Firms Invest in LinDo to Drive Japan Launch of Innovative Drugs
February 19, 2024
- 12 VEGF Inhibitors Ordered to Add Artery Dissection Risk to ADR List
February 19, 2024
- Astellas, Kelonia Join Hands to Develop In Vivo Cell Therapies
February 19, 2024
- UCB Rolls Out gMG Drug Zilbrysq in Japan
February 19, 2024
- Sandoz Launches Promotion for Humira Biosimilar in Japan
February 19, 2024
- Japan Awards Priority Review for Keytruda/Padcev in Bladder Cancer: Astellas
February 19, 2024
- Otsuka’s IgA Nephropathy Drug Gets FDA Breakthrough Tag
February 19, 2024
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…